What is the WHO analgesic ladder and how is it applied in cancer-related pain management?

• A. Step I: non-opioid ± adjuvant for mild pain; Step II: weak opioid ± non-opioid ± adjuvant for moderate pain; Step III: strong opioid ± non-opioid ± adjuvant for severe pain; breakthrough dosing is added and treatment is tailored.
• B. Step I: strong opioid; Step II: non-opioid; Step III: adjuvant therapy; no breakthrough dosing.
• C. Step I: non-opioid only; Step II: opioid only; Step III: there is no Step III.
• D. Step I: adjuvant therapy; Step II: non-opioid; Step III: non-opioid with caffeine.

Answer: (A)

The main idea is a simple, staged approach to cancer pain that grows more potent as pain increases, while using adjuvants and breakthrough dosing to keep relief balanced with safety. At the first tier, mild pain is managed with non-opioids such as acetaminophen or NSAIDs, with adjuvants added as needed for neuropathic or inflammatory components. If pain remains moderate, a weak opioid is added alongside the non-opioid and any adjuvants. For severe pain, a strong opioid becomes the mainstay, again with a non-opioid and suitable adjuvants, and the regimen is tailored to the individual’s response, side effects, and functional goals. A crucial part of this framework is breakthrough dosing—a short-acting opioid given to rapidly control transient spikes in pain, integrated into the overall plan so regular dosing plus rescue doses maintain steady relief. The ladder is flexible and revisited as the patient's pain pattern changes, with adjustments to dose, choice of agents, and the use of adjuvants to optimize comfort while minimizing harms. Adjuvants are used across steps for specific pain types, and routes and schedules are individualized. This description fits the correct option because it accurately reflects the three-tier structure, the inclusion of breakthrough dosing, and the emphasis on tailoring therapy to the patient. The other descriptions misplace the opioid steps or omit breakthrough dosing and the role of adjuvants, which is why they don’t align with how the ladder is applied in practice.